SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is actively trending following Saudi FDA approval for its Anktiva treatment in lung cancer, sparking widespread community discussion about its potential as a game-changing, chemotherapy-free cancer therapy and its global expansion. This news, amplified by public statements from Dr. Patrick Soon-Shiong, is driving intense speculation regarding a short squeeze amidst high market interest.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending due to renewed geopolitical uncertainty as Trump's tariff threats over Greenland escalate US-EU tensions, causing futures to dip. The community is sharply divided, with bears anticipating a significant market correction, while bulls expect a "buy the dip" scenario, recalling previous tariff-related downturns that quickly reversed.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending due to significant insider confidence, highlighted by a director's recent share purchase, and the official groundbreaking of its $100 billion U.S. megafab. The community is actively discussing an unprecedented and sustained shortage in memory chips, especially for AI, driving strong bullish sentiment around the company's strategic expansions and HBM products. Investors are anticipating continued growth as Micron addresses escalating demand.

Alchemy Pay

Alchemy Pay is trending due to significant developments, including its upcoming Level 1 Alchemy Chain and numerous new partnerships and Money Transmitter Licenses expanding its global fiat-crypto on-ramp services. The community is vigorously debating its potential as a payment infrastructure solution, with strong bullish sentiment driven by its enhanced utility and tokenomics.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin is experiencing heightened volatility due to a fresh short report alleging questionable business practices and broader weakness in the ad tech sector. The community is actively debating if recent price movements are fueled by market manipulation and short-selling pressure ahead of anticipated strong earnings. Many bullish investors are emphasizing the company's AI-driven growth, expanding market reach, and recent analyst upgrades, viewing current price levels as a potential buying opportunity.

Uranium Energy Corp. engages in the provision of uranium and titanium mining and related activities, including exploration, pre-extraction, extraction, and processing of uranium concentrates, and titanium minerals. It operates through the following geographical segments: Wyoming, Texas, Saskatchewan, and Others. The company was founded by Alan P. Lindsay and Amir Adnani on May 16, 2003 and is headquartered in Corpus Christi, TX.

Uranium Energy Corp

Uranium Energy Corp is surging to new all-time highs, fueled by rising spot uranium prices and robust bullish sentiment across the nuclear energy sector. The community is actively discussing increasing energy demand from AI and significant government initiatives boosting domestic uranium enrichment. This strong momentum is underpinned by UEC's strategic position as a key US uranium producer with a solid financial standing.

Global X Funds - Global X Copper Miners ETF

Global X Copper Miners ETF (COPX) is actively trending as copper prices surge to new highs, fueled by escalating demand from the AI and green energy sectors. Community discussion highlights a potential 'copper squeeze' due to tight supply and the impact of looming import tariffs. Many traders view COPX as a compelling long-term investment, with some calling copper the 'new oil' amid expectations for continued price appreciation.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is trending as gold surges to new all-time highs, driven by escalating geopolitical tensions, including tariff threats against Europe and concerns around the situation in Iran. The community views gold as a critical safe-haven asset, with ongoing discussions linking its strength to broader uncertainty in global markets and the perceived weakening of fiat currencies.

Global X Funds - Global X DAX Germany ETF

Global X DAX Germany ETF

The Global X DAX Germany ETF is actively discussed amid ongoing US-Europe trade tensions, particularly surrounding escalating tariff threats and Europe's planned fiscal stimulus for defense and infrastructure. Community sentiment remains largely bullish, focusing on Elliott Wave technical setups that suggest continued upside potential, despite recent volatility and broader economic concerns.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is trending amid anticipation of a Supreme Court ruling on tariffs, which could influence inflation and trade stability, alongside ongoing discussions regarding political pressure on the Federal Reserve's independence. This has created a divided community, with some viewing long-term bonds as a potential recession hedge, while others remain bearish due to persistent yield concerns and broader economic uncertainty.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is Humacyte, Inc. (HUMA) Outperforming Other Medical Stocks This Year?

Here is how Humacyte, Inc. (HUMA) and Acrivon Therapeutics, Inc. (ACRV) have performed compared to their sector so far this year.

D. Boral Capital Reiterates "Buy" Rating for Humacyte (NASDAQ:HUMA)

D. Boral Capital reissued a "buy" rating and set a $25.00 price objective on shares of Humacyte in a research report on Monday...

Humacyte, Inc. (NASDAQ:HUMA) Receives Average Recommendation of "Moderate Buy" from Analysts

Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the eight analysts that are currently covering the firm, MarketBeat Ratings reports. One...

Humacyte's (HUMA) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital reiterated a "buy" rating and issued a $25.00 price target on shares of Humacyte in a research note on Monday...

Humacyte (NASDAQ:HUMA) Stock Rating Lowered by Wall Street Zen

Wall Street Zen lowered Humacyte from a "hold" rating to a "sell" rating in a research report on Sunday...

Wall Street Zen Upgrades Humacyte (NASDAQ:HUMA) to "Hold"

Wall Street Zen raised Humacyte from a "sell" rating to a "hold" rating in a research report on Saturday...

Wall Street Analysts See Humacyte, Inc. (HUMA) as a Buy: Should You Invest?

According to the average brokerage recommendation (ABR), one should invest in Humacyte, Inc. (HUMA). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Shares of Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eight brokerages that are presently covering the company, Marketbeat...

CenterBook Partners LP Buys 2,007,743 Shares of Humacyte, Inc. $HUMA

CenterBook Partners LP increased its stake in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 141.1% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange...

Stock Traders Purchase Large Volume of Humacyte Put Options (NASDAQ:HUMA)

Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) saw unusually large options trading activity on Friday. Stock investors purchased 6,057 put options on the stock. This represents an increase of 114...

Humacyte, Inc. engages in the business of developing and manufacturing off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs, and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. The company was founded by Laura E. Niklason, Shannon Dahl, and Juliana L. Blum on October 13, 2004 and is headquartered in Durham, NC.

Current Price	$1.11
Prev Close	$1.10
Open	$1.13
Dividend Yield	0.00%
50-Day Moving Average	$1.19
Beta	1.98
Avg. Volume	4.76M
PE Ratio	-4.65

52-Week High	$4.85
52-Week Low	$0.91
Market Capitalization	$214.23M
EPS (Annual)	-$1.26
Price to Book	-37.11
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

HUMA
Humacyte Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest HUMA News

HUMAHumacyte Inc